Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364395 | 0.87 | ALDH1A1 (0.49) | ALDH1A1FKBP1AHTTSMN1; SMN2MAPK1 | |
| SCHEMBL3369442 | 0.80 | ALDH1A1 (0.44) | ALDH1A1FKBP1ALMNAHTTSMN1; SMN2 | |
| SCHEMBL3366667 | 0.79 | KDM4E (0.43) | ALDH1A1HTTSMN1; SMN2MAPK1NPC1 | |
| SCHEMBL3369449 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNASMN1; SMN2MAPK1NPC1 | |
| SCHEMBL3366078 | 0.78 | HCRTR1 (0.46) | ALDH1A1FKBP1ALMNANPC1MAPT | |
| SCHEMBL3364389 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPK1NPC1NPSR1 | |
| SCHEMBL6069077 | 0.77 | ALDH1A1 (0.44) | ALDH1A1FKBP1AHTTMAPK1NPSR1 | |
| SCHEMBL3367339 | 0.77 | CYP2C19 (0.43) | ALDH1A1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL3368142 | 0.76 | CYP2C19 (0.44) | ALDH1A1FKBP1AHTTMAPK1NPC1 | |
| SCHEMBL3370356 | 0.75 | ALDH1A1 (0.51) | ALDH1A1FKBP1ALMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105538-B2 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2006-09-12 | — | — | US | claimed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | claimed |
| EP-1532141-A1 | 2-PYRROLIDIN-2-YL- 1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | Grünenthal GmbH (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004024725-A1 | 2-PYRROLIDIN-2-YL-[1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | Grünenthal GmbH (DE) | 2004-03-25 | — | — | WO | claimed |
| EP-1532141-B1 | 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | GRUENENTHAL GMBH (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7105538-B2 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
| EP-1532141-A1 | 2-PYRROLIDIN-2-YL- 1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | Grünenthal GmbH (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004024725-A1 | 2-PYRROLIDIN-2-YL-[1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | Grünenthal GmbH (DE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | OPRD1, OPRK1, GRIN2C | ALDH1A1 510/4885CYP11B1 455/4885FKBP1A 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.